Market By Type, Industry Verticals, And Country | Forecast 2021-2028
Triton’s research report suggested that the European non-alcoholic steatohepatitis (NASH) biomarker market is appraised to garner a CAGR of 20.19% during the expected years of 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries scrutinized in this market comprise:
•       The UK
•       Spain
•       Germany
•       Italy
•       France
•       Russia
•       Rest of Europe
In the region, the surge in the prevalence of NASH, along with the rise in the geriatric population, is predicted to drive the progress of the examined market over the forecast period. Additionally, the increase in awareness pertaining to non-alcoholic fatty liver diseases and the rise in R&D activities to develop NASH therapeutics are augmenting the development of the non-alcoholic steatohepatitis biomarker market across Europe.
In Germany, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are essentially causing the development of cirrhosis and hepatocellular carcinoma. The country is likely to observe an increase in these diseases, owing to the rise in obesity, diabetes, and metabolic syndrome among the population. Further, there is a substantial rise in the obesity rates among children and adolescents, as stated by WHO. This high prevalence will eventually lead to the development of NASH and other conditions. All these factors are predicted to widen the scope of the NASH biomarker market in Germany in the next few years.
On the other hand, there is a surge in the number of clinical trials for non-alcoholic fatty liver disease in France. Although there are no specific drugs and diagnostics available in the market, they will likely enter the market in the upcoming years. Hence, the growing clinical trials are evaluated to positively impact the non-alcoholic steatohepatitis (NASH) biomarker market over the assessed period.
Genfit SA is a biopharmaceutical company involved in developing drugs and biomarkers in areas that lack effective treatments or diagnostic tools. It primarily focuses on its R&D activities to participate in the potential commercialization of treatment solutions to combat metabolic and inflammatory diseases, specifically affecting the liver. Among its products, elafibranor, a drug candidate, is currently evaluated under its phase 3 clinical trial to treat NASH. Genfit was founded in 1999 and is headquartered in France.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1. CONTRACTS & PARTNERSHIPS
2.6.2. BUSINESS EXPANSIONS & DIVESTITURES
2.6.3. ACQUISITIONS & MERGERS
2.6.4. NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK
5.1. GERMANY
5.2. FRANCE
5.3. UNITED KINGDOM
5.4. ITALY
5.5. RUSSIA
5.6. SPAIN
5.7. REST OF EUROPE
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1. OBJECTIVES OF STUDY
7.1.2. SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1. PRIMARY DATA SOURCES
7.2.2. SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1. EVALUATION OF PROPOSED MARKET
7.3.2. IDENTIFICATION OF DATA SOURCES
7.3.3. ASSESSMENT OF MARKET DETERMINANTS
7.3.4. DATA COLLECTION
7.3.5. DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 16:Â UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 17:Â ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 18:Â RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 19:Â SPAIN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 20:Â REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)